PMID- 28741529
OWN - NLM
STAT- MEDLINE
DCOM- 20180118
LR  - 20211204
IS  - 2405-8025 (Electronic)
IS  - 2405-8025 (Linking)
VI  - 2
IP  - 3
DP  - 2016 Mar
TI  - Amphiregulin in Cancer: New Insights for Translational Medicine.
PG  - 111-113
LID - S2405-8033(16)00032-7 [pii]
LID - 10.1016/j.trecan.2016.02.002 [doi]
AB  - Although there is a large body of literature regarding amphiregulin (AREG) in 
      human cancer, most knowledge focuses on its cell-autonomous functions in 
      epithelial malignancies. Recent studies revealed that AREG is also present in the 
      tumor microenvironment (TME) and contributes to therapeutic resistance. We 
      discuss emerging concepts of AREG tumor biology and highlight their implications 
      for translational medicine.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Xu, Qixia
AU  - Xu Q
AD  - Key Lab of Stem Cell Biology, Institute of Health Sciences, Shanghai Institutes 
      for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiaotong 
      University School of Medicine, Shanghai 200031, China; Collaborative Innovation 
      Center of Systems Biomedicine, Shanghai Jiaotong University School of Medicine, 
      Shanghai 200240, China.
FAU - Chiao, Paul
AU  - Chiao P
AD  - Department of Molecular and Cellular Oncology, The University of Texas MD 
      Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Sun, Yu
AU  - Sun Y
AD  - Key Lab of Stem Cell Biology, Institute of Health Sciences, Shanghai Institutes 
      for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiaotong 
      University School of Medicine, Shanghai 200031, China; Collaborative Innovation 
      Center of Systems Biomedicine, Shanghai Jiaotong University School of Medicine, 
      Shanghai 200240, China; Department of Medicine and VAPSHCS, University of 
      Washington, Seattle, WA 98195, USA. Electronic address: sunyu@sibs.ac.cn.
LA  - eng
PT  - Journal Article
DEP - 20160302
PL  - United States
TA  - Trends Cancer
JT  - Trends in cancer
JID - 101665956
RN  - 0 (Amphiregulin)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - *Amphiregulin/immunology/metabolism
MH  - Biomarkers, Tumor/immunology/metabolism
MH  - Humans
MH  - *Neoplasms/immunology/metabolism/therapy
MH  - Translational Research, Biomedical
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - amphiregulin
OT  - immunosuppression
OT  - secretory phenotype
OT  - therapeutic resistance
OT  - translational medicine
OT  - tumor microenvironment
EDAT- 2016/03/01 00:00
MHDA- 2018/01/19 06:00
CRDT- 2017/07/26 06:00
PHST- 2015/12/18 00:00 [received]
PHST- 2016/02/05 00:00 [revised]
PHST- 2016/02/08 00:00 [accepted]
PHST- 2017/07/26 06:00 [entrez]
PHST- 2016/03/01 00:00 [pubmed]
PHST- 2018/01/19 06:00 [medline]
AID - S2405-8033(16)00032-7 [pii]
AID - 10.1016/j.trecan.2016.02.002 [doi]
PST - ppublish
SO  - Trends Cancer. 2016 Mar;2(3):111-113. doi: 10.1016/j.trecan.2016.02.002. Epub 
      2016 Mar 2.